The Ministry of Health and Family Welfare has proposed a separate licensing framework for the wholesale trade of bulk drugs, including active and inactive bulk substances, to strengthen regulatory oversight and accountability in the pharmaceutical supply chain.
The proposed amendments to the Drugs Rules, 1945, seek to introduce separate application and licence forms for the wholesale of bulk drugs, distinct from the existing licensing provisions for formulations. At present, a common licence covers the wholesale of both formulations and bulk drugs. The ministry said the dedicated framework would enable more focused regulatory oversight of bulk drug wholesale trade and greater accountability in the pharmaceutical supply chain.
The proposal was agreed upon by the Drugs Consultative Committee at its 67th meeting on November 17, 2025, and by the Drugs Technical Advisory Board at its 93rd meeting on February 16, 2026. Under the proposed framework, the licence will capture the categories of bulk drugs handled by wholesalers, including drugs covered under the Narcotic Drugs and Psychotropic Substances Act, 1985. The sale of bulk drugs will be carried out under the supervision of a competent person, the ministry said.
Upon implementation, the amendment is expected to give better control over the wholesale of bulk drugs and strengthen enforcement in relation to antimicrobial resistance and the movement of NDPS drugs, the ministry added. Existing licensees will be given adequate time to comply; the new requirements will apply only upon expiry of their current retention period or 12 months after the final publication of the amendment, whichever is later. The ministry has invited objections and suggestions from stakeholders and the public within 30 days from the date the draft rules are made available.